Cytokinetics Sees Myqorzo Launch Strength Carry Into 2027, RBC Says

MT Newswires Live10-15

Cytokinetics (CYTK) expects further acceleration of its Myqorzo, a heart-disease treatment, especially into 2027, RBC Capital Markets said Wednesday in a report.

Management expressed confidence in Myqorzo's launch, citing prescriber activation, market growth, the product's differentiated profile, and potential label expansions as factors to inflect the launch curve and drive revenue faster, RBC said.

Myqorzo treats obstructive hypertrophic cardiomyopathy, a condition in which the heart muscle becomes abnormally thick and restricts blood flow.

Cytokinetics is on track to reach its targeted new patient starts by year-end and expects further share growth in 2027, backed by commercial momentum and clinical support, the report said. Feedback from RBC's industry experts align with the company's bullish view, the analysis said.

Based on the trends, revenue targets of $152 million for 2026 and $505 million are "achievable," RBC said.

RBC has an outperform rating on Cytokinetics stock with a $113 price target.

Price: 64.43, Change: +1.00, Percent Change: +1.58

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment